Patients were randomly assigned to either continue methotrexate with placebo (dummy pill) or combine methotrexate with a second DMARD (leflunomide). Dosages of methotrexate were 10 to 20 mg weekly. Dosages of leflunomide were usually 10 to 20 mg daily. Neither the patients nor their physicians were told who got leflunomide or dummy pills. At 6 months, the researchers asked about joint symptoms, pain intensity, ability to function, and various side effects. They also did blood tests to monitor levels of joint inflammation and check for possible liver toxicity from the DMARDs.